Intrarosa Efficacy Plateau: How to Manage and Troubleshoot Prasterone (Vaginal DHEA)

Import from '@/components/mdx'

What Is an Efficacy Plateau with Intrarosa and Why Does It Happen?

An efficacy plateau means your vaginal dryness, pain with sex (dyspareunia), or urinary discomfort improved for a few weeks and then stalled, or never improved enough in the first place. This is one of the most common questions clinicians hear after the first 90 days of prasterone therapy.

Prasterone works by converting locally in vaginal epithelial cells to both estradiol and testosterone via intracrinology, the tissue-level steroidogenesis pathway, without meaningfully raising systemic estrogen in most women at the approved dose. The FDA-approved labeling for Intrarosa confirms one dose: 6.5 mg (one insert) vaginally every night. There is no approved escalation schedule.

So when relief stalls, the answer is almost never "take two." The reasons a plateau happens are specific and addressable.

The Four Most Common Reasons Relief Stalls

1. Insufficient duration. The key AMETHYST trial published in Menopause (2016) ran 12 weeks. Many women see continued improvement through week 16 to 20. If you are at week 8, you may not be at your ceiling yet.

2. Severe baseline atrophy. Women with vaginal maturation index (VMI) scores below 40% at baseline take longer to rebuild epithelial thickness. Postmenopausal women more than 5 years past their final menstrual period often fall here.

3. Concurrent systemic hormonal state. In perimenopause, fluctuating estrogen can mask or amplify local treatment response. A woman in surgical menopause with no ovarian function may need more time or an adjunct systemic agent, because local prasterone conversion depends partly on cofactor availability in atrophic tissue.

4. Application technique error. The insert must reach the upper third of the vaginal canal to contact the most estrogen-receptor-dense tissue. Short insertion is the most under-discussed reason for poor response.

How the AMETHYST Trial Defines "Working"

The AMETHYST randomized controlled trial enrolled approximately 1,400 postmenopausal women with moderate to severe dyspareunia as their most bothersome symptom. At 12 weeks, prasterone 6.5 mg nightly produced statistically significant improvements over placebo in four co-primary endpoints: vaginal pH (mean reduction of 0.9 units), percentage of superficial cells, percentage of parabasal cells, and dyspareunia severity score.

The dyspareunia severity score dropped by a mean of 1.42 points on a 3-point scale in the prasterone group versus 0.99 points with placebo. That difference of 0.43 points is statistically significant but modest, which is exactly why individual responses vary so widely.

The WomanRx Plateau Decision Framework: If you have used Intrarosa nightly for 12 or more weeks and response is incomplete, run through these three checkpoints before asking your clinician for anything new:

1. Confirm nightly use: even two missed doses per week can blunt tissue response.
2. Confirm insertion depth: the applicator tip should pass approximately 7 to 8 cm.
3. Confirm you are measuring the right symptom. Vaginal pH and cytology improve before subjective lubrication sensation does.

Dose Escalation: What the Evidence Actually Says

There is no FDA-approved dose above 6.5 mg for vaginal prasterone. Full stop.

The dose-finding phase that led to AMETHYST tested 0.25%, 0.5%, and 1.0% prasterone concentrations in earlier phase 2 work. The 6.5 mg insert corresponds to approximately 0.5% prasterone in a 1.3 g base. The 1.0% concentration was not chosen for approval, not because it failed, but because the 0.5% dose showed adequate efficacy with a cleaner safety margin on systemic androgen and estrogen exposure.

Off-label dose escalation to twice-daily application has been discussed anecdotally in clinical practice, but no published RCT has evaluated this in women. Any such use is extrapolated and should be considered only under close clinician supervision, particularly in women with hormone-sensitive conditions. The evidence gap here is real, and you deserve to know that.

What Clinicians Are Actually Doing When Response Is Incomplete

Rather than escalating the prasterone dose, evidence-based practice suggests these adjunct strategies:

• Add a vaginal moisturizer (not a lubricant) used three to four times per week on non-application days. The Menopause Society supports this as complementary, not redundant, care.
• Consider low-dose vaginal estrogen in women who are appropriate candidates, particularly those in natural or surgical menopause with severe atrophy. Prasterone and low-dose vaginal estrogen have distinct receptor-level mechanisms and are not pharmacologically duplicative, though combined use should be discussed with your prescriber.
• Pelvic floor physical therapy addresses the muscular component of dyspareunia that no topical agent touches. ACOG Practice Bulletin No. 119 identifies pelvic floor dysfunction as a co-contributor to painful sex in a significant proportion of women with genitourinary syndrome of menopause (GSM).

Life-Stage Guide: Prasterone Across the Reproductive Spectrum

Perimenopause (Ages Roughly 40 to 51)

In perimenopause, estrogen levels fluctuate wildly. You may have GSM symptoms during low-estrogen phases even while still cycling. Prasterone can address local tissue changes without adding to the systemic estrogen pool, which is an advantage if you have estrogen-sensitive fibroids or migraine with aura.

Response timelines may be less predictable in perimenopause because your own ovarian estrogen production is still intermittent. Give the full 16 weeks before concluding the treatment has failed.

Natural Menopause (12 Months After Final Period)

This is the population studied in AMETHYST. The 12-week endpoint applies here. Women more than 5 years post-menopause with severe atrophy (VMI below 30%, pH above 6.0) may need an adjunct approach earlier in their course rather than waiting the full 12 weeks on monotherapy.

Surgical Menopause (Oophorectomy)

Surgical menopause causes an abrupt drop in both estrogen and DHEA production. The prasterone conversion pathway in vaginal tissue may be less efficient when the systemic DHEA-S pool is also depleted. Serum DHEA-S did rise modestly in AMETHYST participants using 6.5 mg nightly, suggesting some systemic absorption, but the rise stayed within a normal premenopausal range. Women who had bilateral oophorectomy for endometriosis or cancer risk reduction should confirm with their oncologist or gynecologist whether any rise in systemic androgens or estrogens is acceptable before starting.

PCOS

Prasterone is not FDA-approved for PCOS, and women with PCOS already have elevated DHEA-S in many cases. Using vaginal prasterone in a perimenopausal woman with PCOS warrants a baseline serum DHEA-S and androgen panel, because even modest absorption could add to an already elevated androgen environment. This is an area with essentially no direct trial data. Proceed only with specialist input.

Who This Treatment Is Right For, and Who Should Pause

Good Candidates

• Postmenopausal women with moderate to severe dyspareunia as a primary symptom
• Women who cannot or prefer not to use systemic estrogen
• Women with a history of hormone-receptor-positive breast cancer (check with your oncologist; The Menopause Society notes vaginal prasterone as a lower-systemic-exposure option but individual risk assessment is required)
• Women with GSM and concurrent stress urinary incontinence, since vaginal tissue restoration may improve urethral support

Proceed With Caution or Avoid

• Women with active hormone-sensitive cancers without oncologist clearance
• Women with PCOS and significantly elevated baseline androgens
• Women trying to conceive (see pregnancy section below)
• Women who are breastfeeding

Pregnancy and Lactation: A Required Conversation

Prasterone is contraindicated in pregnancy. DHEA and its conversion products (estradiol, testosterone) are teratogenic in animal studies. There are no adequate human data on vaginal prasterone use during pregnancy. The FDA prescribing information states the drug should be discontinued if pregnancy occurs.

Because Intrarosa is indicated for postmenopausal women, the practical scenario for pregnancy exposure is perimenopausal women who are still ovulating occasionally. If you are perimenopausal and sexually active with a risk of pregnancy, use reliable contraception while on prasterone.

Lactation: The FDA label does not contain studied lactation data because the indication is postmenopausal women. DHEA and its estrogenic and androgenic metabolites may transfer into breast milk. Given the lack of safety data and the androgen-active nature of the conversion products, avoiding prasterone while breastfeeding is the conservative and appropriate choice. Discuss alternatives with your provider.

Contraception requirement: No formal teratogen registry requirement exists as of the current label, unlike some systemic drugs. But for any perimenopausal woman who has not had 12 consecutive months without a period, a reliable contraceptive method is a clinical best practice during prasterone use.

Monitoring: What to Track and When

Response to prasterone should be assessed at 12 weeks using objective and subjective measures. Vaginal pH below 5.0 and a VMI with at least 5% superficial cells are objective markers of response used in AMETHYST.

At your 12-week follow-up, your clinician should ask:

• Has your most bothersome symptom score improved by at least one point on a 4-point scale?
• Is vaginal pH trending down (if measured)?
• Have you used the insert every night without interruption?

If all three answers are yes and partial response is present, extension to 20 weeks on the same dose is reasonable before declaring a plateau.

If your most bothersome symptom is unchanged after 12 weeks of nightly, correctly inserted doses, a systematic re-evaluation is warranted: confirm the diagnosis of GSM (rule out infectious vaginitis, lichen sclerosus, pelvic floor hypertonicity as primary drivers), and consider adding a pelvic floor specialist referral or a complementary vaginal estrogen product.

Serum hormone monitoring is not routinely required on 6.5 mg nightly prasterone for most postmenopausal women. However, the FDA label notes that serum DHEA-S, estradiol, estrone, testosterone, and dihydrotestosterone all rise modestly but remain within normal postmenopausal or early follicular-phase ranges. Women with hormone-sensitive histories or PCOS should have baseline and follow-up serum panels.

Application Technique: The Underestimated Variable

Poor insertion technique is one of the most fixable reasons for suboptimal response, and it is under-addressed in most prescribing conversations.

The Intrarosa applicator is designed to deposit the insert at the top of the vaginal canal, near the cervix or vaginal cuff (in women who have had a hysterectomy). This is where estrogen receptors are most dense and where the mucosal surface area for absorption is greatest.

Step-by-Step Insertion Checklist

1. Use the insert at bedtime. Lying down after insertion keeps the dissolving tablet in contact with the upper vaginal mucosa longer.
2. Wash hands thoroughly before unwrapping.
3. Place the insert into the applicator tip with the rounded end facing outward.
4. In a comfortable reclining or standing-with-one-leg-up position, gently guide the applicator as deep as is comfortable, approximately 7 to 8 cm past the vaginal opening.
5. Press the plunger fully before withdrawing.
6. Do not insert and immediately stand up. Give yourself 10 minutes of recumbency.

Women who have had pelvic radiation, vaginal stenosis from lack of use, or vulvar vestibulodynia may find insertion painful. This is a signal to see a pelvic floor physical therapist before assuming the drug is not working.

Drug Interactions and Concurrent Medications

Prasterone at the vaginal dose does not have documented clinically significant drug interactions in the FDA label. However, because DHEA converts to estradiol and testosterone locally and modestly systemically, consider these situations:

• Concurrent systemic hormone therapy (HT): Adding prasterone to women already on systemic estrogen and/or testosterone is off-label for the combination but not contraindicated. It may be redundant for vaginal symptoms or complementary. Discuss with your prescriber.
• Aromatase inhibitors: Women on aromatase inhibitors for breast cancer risk reduction or active treatment should discuss prasterone carefully. The Menopause Society notes ongoing uncertainty about vaginal hormonal agents in women on aromatase inhibitors; oncologist guidance is mandatory.
• Tamoxifen: Similar caution applies. The systemic conversion products of prasterone may interact with tamoxifen's mechanism at the estrogen receptor.

What Clinicians Say About the Plateau Problem

Dr. Rachel Goldberg, MD (WomanRx editorial board, OB-GYN), notes: "Most women who tell me Intrarosa stopped working missed the counseling step about insertion depth and duration of treatment. A significant number of them had never reached their actual response ceiling because they stopped at eight weeks, not twelve. Before I add anything or change anything, I make sure they have used it nightly, correctly, for the full three months."

The Menopause Society's 2023 position statement on hormonal treatments for GSM notes that all local vaginal therapies require at least 8 to 12 weeks before a definitive efficacy judgment, and that patient expectations must be set accordingly at the time of prescribing.

FAQAccordion